JP4685241B2 - 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法 - Google Patents

疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法 Download PDF

Info

Publication number
JP4685241B2
JP4685241B2 JP2000575892A JP2000575892A JP4685241B2 JP 4685241 B2 JP4685241 B2 JP 4685241B2 JP 2000575892 A JP2000575892 A JP 2000575892A JP 2000575892 A JP2000575892 A JP 2000575892A JP 4685241 B2 JP4685241 B2 JP 4685241B2
Authority
JP
Japan
Prior art keywords
receptor
receptors
protein
orphan
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000575892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527727A5 (enExample
JP2002527727A (ja
Inventor
ベハン，ドミニク・ピー
シヤルマース，デレク・テイ
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2002527727A publication Critical patent/JP2002527727A/ja
Publication of JP2002527727A5 publication Critical patent/JP2002527727A5/ja
Application granted granted Critical
Publication of JP4685241B2 publication Critical patent/JP4685241B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000575892A 1998-10-13 1999-10-12 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法 Expired - Fee Related JP4685241B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/170,496 1998-10-13
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
PCT/US1999/023935 WO2000021987A2 (en) 1998-10-13 1999-10-12 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease

Publications (3)

Publication Number Publication Date
JP2002527727A JP2002527727A (ja) 2002-08-27
JP2002527727A5 JP2002527727A5 (enExample) 2006-11-30
JP4685241B2 true JP4685241B2 (ja) 2011-05-18

Family

ID=22620080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000576019A Expired - Fee Related JP4672866B2 (ja) 1998-10-13 1999-10-12 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体
JP2000575892A Expired - Fee Related JP4685241B2 (ja) 1998-10-13 1999-10-12 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000576019A Expired - Fee Related JP4672866B2 (ja) 1998-10-13 1999-10-12 非内因性の構成的に活性化されたヒトｇタンパク質共役受容体

Country Status (14)

Country Link
US (2) US6555339B1 (enExample)
EP (1) EP1121431B9 (enExample)
JP (2) JP4672866B2 (enExample)
KR (1) KR100598752B1 (enExample)
CN (1) CN1329511C (enExample)
AT (1) ATE318311T1 (enExample)
AU (5) AU769987B2 (enExample)
CA (1) CA2342314A1 (enExample)
DE (3) DE1121431T1 (enExample)
DK (1) DK1121431T5 (enExample)
ES (1) ES2163384T3 (enExample)
IL (2) IL141965A0 (enExample)
NZ (1) NZ510331A (enExample)
WO (2) WO2000021987A2 (enExample)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
ES2308759T3 (es) * 1998-11-20 2008-12-01 Arena Pharmaceuticals, Inc. Receptores acoplados a proteina g humanos huerfanos.
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
EP1235931A2 (en) * 1999-07-30 2002-09-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
JP2003518628A (ja) * 1999-12-10 2003-06-10 アストラゼネカ アクチボラグ 化合物
EP1265922A2 (en) * 1999-12-17 2002-12-18 AstraZeneca AB Agonists and antagonists of the receptor gpr19 and their use in appetite control
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
US20030113810A1 (en) * 2000-02-18 2003-06-19 Alan Wise Novel assay
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
WO2001064872A2 (en) * 2000-02-29 2001-09-07 Millennium Pharmaceuticals, Inc. Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
MXPA02010241A (es) * 2000-04-26 2004-09-06 Aventis Pharma Gmbh Receptor edg8, su preparacion y uso.
EP1149907A1 (en) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH EDG8 receptor, its preparation and use
JP2003531637A (ja) * 2000-05-03 2003-10-28 アストラゼネカ アクチボラグ 方 法
AU2001274522A1 (en) * 2000-06-15 2001-12-24 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
AU2001268471A1 (en) * 2000-06-16 2002-01-02 Incyte Genomics, Inc. G-protein coupled receptors
CA2413195C (en) 2000-06-21 2012-01-17 Takeda Chemical Industries, Ltd. Ligand to gpr8 and dna thereof
WO2002002767A1 (fr) * 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Proteine de recepteur couple a la proteine g et adn correspondant
EP1364017A2 (en) * 2000-08-18 2003-11-26 Novartis AG Inflammation related g-protein coupled receptor
WO2002018590A2 (en) * 2000-08-30 2002-03-07 John Hopkins University School Of Medicine Identification of activated receptors and ion channels
AU2000276780A1 (en) * 2000-10-02 2001-04-23 Biofocus Discovery Limited Cellular receptor mutations predicted by multiple-sequence-allignment
EP1344823A4 (en) * 2000-11-30 2005-03-16 Takeda Chemical Industries Ltd NEW G-PROTEIN-COUPLED RECEPTOR PROTEINS AND THEIR DNAS
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
CA2439383A1 (en) * 2001-02-26 2002-09-06 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) * 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
ATE371863T1 (de) * 2001-05-15 2007-09-15 Takeda Pharmaceutical Screening-verfahren
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
EP1404708A4 (en) * 2001-06-05 2005-01-19 Arena Pharm Inc NON-ENDED, CONSTITUTIVELY ACTIVATED VERSIONS OF THE G-PROTEIN-COUPLED RECEPTOR GCR1 FROM PLANTS
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
WO2003006504A2 (en) * 2001-07-13 2003-01-23 Akzo Nobel N.V. Allelic variants of gpr50
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
EP1450666A4 (en) * 2001-11-05 2008-11-12 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR TREATING HEART CIRCULAR ILLNESSES USING 139,258,1261,1486,2398,2414,7660,8587,10183,10550,12680,17921,32248,60489 OR 93804
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
DK1463759T3 (da) 2002-01-07 2013-08-12 Euroscreen Sa Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
EP1336655A1 (en) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Method of identifying protein CAMS (constitutively active mutants)
US20030175889A1 (en) * 2002-01-23 2003-09-18 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR
WO2003066077A2 (en) * 2002-02-06 2003-08-14 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
EP1479768B1 (en) 2002-02-14 2010-04-28 Takeda Pharmaceutical Company Limited Novel screening method
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
AU2003241037A1 (en) * 2002-06-08 2003-12-22 Astrazeneca Ab Methods for the detection of polymorphisms in human gpr50
CA2494607A1 (en) * 2002-08-01 2004-02-12 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
WO2004015427A2 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
AU2003251471A1 (en) * 2002-08-06 2004-02-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
JPWO2004017994A1 (ja) * 2002-08-22 2005-12-08 協和醗酵工業株式会社 喘息の予防および／または治療剤
AU2003276106A1 (en) * 2002-10-24 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7056685B1 (en) * 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
EP1562943A1 (en) 2002-11-06 2005-08-17 Amgen Inc. Fused heterocyclic compounds
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003297644A1 (en) * 2002-12-04 2004-06-23 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2004083394A2 (en) * 2003-03-18 2004-09-30 Arena Pharmaceuticals Inc. Human g protein-coupled receptors and modulators thereof for the treatment of inflammatory disorders
JPWO2004093912A1 (ja) * 2003-04-23 2006-07-13 協和醗酵工業株式会社 好中球性炎症疾患の予防および／または治療剤
US20080009551A1 (en) * 2003-04-30 2008-01-10 Arena Pharmaceuticals, Inc. Methods and Compositions for Identifying Modulators of G Protein-Coupled Receptors
CA2525286C (en) * 2003-05-20 2012-09-11 The University Court Of The University Of Glasgow Materials and methods relating to g-protein coupled receptor oligomers
ATE405827T1 (de) * 2003-09-11 2008-09-15 Takeda Pharmaceutical Screening-verfahren
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
EP1684764A2 (en) * 2003-10-09 2006-08-02 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists
WO2005040829A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A2 (en) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040828A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005040825A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005074980A1 (en) * 2004-01-29 2005-08-18 Cellzome Ag Treatment of neurodegenerative diseases by the use of gpr49
CA2556757C (en) 2004-02-20 2011-05-03 Aventis Pharmaceuticals Inc. Oxydecahydronaphthalene modulators of hm74
WO2005101005A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
ATE486962T1 (de) * 2004-04-27 2010-11-15 Takeda Pharmaceutical Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JP2009511063A (ja) * 2005-10-14 2009-03-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ２２およびそれに関連する方法
US7998685B2 (en) * 2005-11-10 2011-08-16 Arena Pharmaceuticals, Inc. Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
HRP20120336T1 (hr) 2007-03-22 2012-05-31 Heptares Therapeutics Limited Receptori vezani na mutacije g-proteina i metode njihovog odabira
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
WO2010091692A2 (en) * 2009-04-30 2010-08-19 H. Lundbeck A/S Constitutively active mutants and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
SMT201800346T1 (it) 2012-10-12 2018-09-13 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
WO2014057122A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびその結合体
EP2968596B1 (en) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
BR112016001542A2 (pt) 2013-07-25 2017-08-29 Novartis Ag Polipeptídios cíclicos para o tratamento de insuficiência cardíaca
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
CA2945706C (en) 2014-04-25 2023-10-24 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3416640A1 (en) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
EP3416641A1 (en) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20220156974A (ko) 2017-09-20 2022-11-28 주식회사 피에이치파마 타일란스타틴 유사체
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN119752801A (zh) * 2018-08-01 2025-04-04 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2025207642A1 (en) * 2024-03-25 2025-10-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Cxcr3 isoforms to improve recombinant receptor trafficking

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7492291A (en) 1990-02-26 1991-09-18 Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
DE69232876D1 (de) 1991-10-01 2003-01-30 Us Gov Health & Human Serv Ein verfahren zur identifikation von liganden und ligandantagonisten
AU685054C (en) * 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
AU677968B2 (en) 1992-09-25 1997-05-15 H. Lundbeck A/S DNA encoding human alpha 1 adrenergic receptors and uses thereof
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
AU1173995A (en) 1993-11-10 1995-05-29 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
EP0743520A3 (en) * 1993-12-30 1999-11-10 The Salk Institute For Biological Studies Novel uses for GAL4-receptor constructs
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
US6114139A (en) 1994-08-11 2000-09-05 Takeda Chemical Industries, Ltd. G-protein coupled receptor protein and a DNA encoding the receptor
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
WO1996039442A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. G-protein receptor htnad29
WO1997011159A1 (en) 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
EP0869975B1 (en) 1995-12-11 2007-08-15 New England Medical Center Hospitals, Inc. Assay for and uses of peptide hormone receptor ligands
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
AU3648297A (en) 1996-07-02 1998-01-21 President And Fellows Of Harvard College Receptor tyrosine phosphatase, and uses related thereto
WO1998013513A2 (en) * 1996-09-24 1998-04-02 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
EP0960125A4 (en) 1996-12-27 2002-09-25 Merck & Co Inc GALANIN RECEPTOR GalR2 AND NUCLEOTIDES ENCODING SAME
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
WO1998038217A1 (en) 1997-02-27 1998-09-03 Milt Teitler Constitutively activated serotonin receptors
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU743259B2 (en) 1997-04-14 2002-01-24 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (en) 1997-04-22 2000-04-19 Smithkline Beecham Corporation cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor
JP2002508660A (ja) 1997-06-12 2002-03-19 スミスクライン ビーチャム コーポレーション Ｈｍ７４ａ受容体
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
WO1999024569A1 (fr) 1997-11-11 1999-05-20 Ono Pharmaceutical Co., Ltd. Recepteur d'acide lysophosphatidique humain et utilisation dudit recepteur
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
DE69941330D1 (de) 1998-03-26 2009-10-08 Univ R Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
US6107324A (en) 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
AU751080B2 (en) * 1998-07-31 2002-08-08 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
US6777204B1 (en) 1998-09-03 2004-08-17 Asahi Kasei Kabushiki Kaisha Receptor protein and method for diagnosing inflammatory diseases by using the same
NZ510712A (en) 1998-10-13 2004-11-26 Arena Pharm Inc Non-endogenous, constitutively activated human G protein-coupled receptors
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
CN1341123A (zh) 1999-02-19 2002-03-20 武田药品工业株式会社 新型g蛋白偶联型受体蛋白及其dna
AU764310B2 (en) 1999-07-15 2003-08-14 Solvay Pharmaceuticals B.V. Human G-protein coupled receptor
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
CA2381979A1 (en) 1999-08-17 2001-02-22 Klaus Ducker Pgpcr-3 polypeptides and dna sequences thereof
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
CA2386509A1 (en) 1999-10-27 2001-05-03 Pharmacia & Upjohn Company G protein-coupled receptors expressed in human brain
AU782959B2 (en) 1999-11-17 2005-09-15 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors

Also Published As

Publication number Publication date
AU2011200016A1 (en) 2011-01-27
WO2000022129A9 (en) 2000-09-14
DK1121431T3 (da) 2006-06-26
DE1121431T1 (de) 2002-05-23
US7410777B2 (en) 2008-08-12
NZ510331A (en) 2004-07-30
WO2000021987A9 (en) 2000-08-24
DK1121431T5 (da) 2008-03-03
WO2000021987A2 (en) 2000-04-20
EP1121431B9 (en) 2007-10-24
CN1329511C (zh) 2007-08-01
DE69929993T2 (de) 2006-10-26
EP1121431B1 (en) 2006-02-22
AU2004203102B2 (en) 2007-10-18
US6555339B1 (en) 2003-04-29
ATE318311T1 (de) 2006-03-15
DE69929993D1 (de) 2006-04-27
JP2003531565A (ja) 2003-10-28
US20030105292A1 (en) 2003-06-05
AU2008200231A1 (en) 2008-02-07
WO2000021987A3 (en) 2000-07-13
AU769987B2 (en) 2004-02-12
AU6430799A (en) 2000-05-01
ES2163384T1 (es) 2002-02-01
EP1121431A1 (en) 2001-08-08
AU2004203102A1 (en) 2004-07-29
ES2163384T3 (es) 2006-12-01
WO2000022129A1 (en) 2000-04-20
DE69929993T4 (de) 2008-08-28
IL141965A0 (en) 2002-03-10
CN1398298A (zh) 2003-02-19
KR20010085911A (ko) 2001-09-07
AU2011200511A1 (en) 2011-03-03
CA2342314A1 (en) 2000-04-20
JP2002527727A (ja) 2002-08-27
IL141965A (en) 2008-08-07
JP4672866B2 (ja) 2011-04-20
HK1038040A1 (en) 2002-03-01
KR100598752B1 (ko) 2006-07-11

Similar Documents

Publication Publication Date Title
JP4685241B2 (ja) 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法
Milligan et al. Heterotrimeric G‐proteins: a short history
US20060160135A1 (en) SF-1 and LRH-1 modulator development
EP0965041B1 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
JP2000106888A (ja) 新規ｇ―タンパク質結合レセプタ―（ｈｆｇａｎ７２ｙ）
WO1998046995A9 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
JP2001505779A (ja) Ｐｙｋ２関連産物および方法
JP7676323B2 (ja) Ｇｐｃｒヘテロマー阻害剤及びその使用
US6045797A (en) Treatment or diagnosis of diseases or conditions associated with a BLM domain
KR100977824B1 (ko) Ｅｐｆ 수용체 에세이, 화합물 및 치료학적 조성물
JP2003513629A (ja) 新規なｇｐｃｒ＿ｋｄ５ポリペプチドおよびそのｄｎａ配列
JP2002538768A (ja) イオンチャンネル、特にバニロイド受容体様（ｖｒ−ｌ）受容体
EP0797662A1 (en) Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction
KR20000070545A (ko) 질병 치료에 유용한 세포 표면막 수용체 조절제의 확인 방법
Seyedabadi et al. Receptor-Arrestin Interactions: The GPCR Perspective. Biomolecules 2021, 11, 218
Babin Kinetic Analysis of CGRP and Adrenomedullin Receptor Signaling
Anton Characterization of CAMP Nanodomains Surrounding the Human Glucagon-like Peptide 1 Receptor Using FRET-based Reporters: Charakterisierung Der Rezeptor-assoziierten CAMP Nanodomänen Des Humanen Glucagon-like Peptide 1 Rezeptors Mittels FRET-basierter Sensoren
Liu et al. Dimerization‐dependent NOTCH receptor transactivation unveils a class of highly selective NOTCH signalling inhibitors
Lilley Novel insights into the interaction between GPRC6A and receptor activity modifying proteins
Singh Characterization Of Reactive Oxygen Species As Signal Transducers In Beta2-adrenergic Receptor Signaling And Evaluation Of Their Role In Receptor-beta-arrestin Interactions.
GB2364057A (en) G protein coupled receptor
JP2005526981A (ja) ニューロメジンｕ受容体２（ｎｍｕ２）の診断および治療的使用
JP2002238578A (ja) ラットｅｄｇ７受容体
US20020037550A1 (en) Molecular cloning of a mouse seven transmembrane receptor (AXOR70)
JP2001029083A (ja) 新規なｇ蛋白質共役型レセプター

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090731

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110210

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees